IP Library Granted Patent US 10,624,838
Granted Patent B2
US 10,624,838 · App. 14/904,151 · Granted Apr 21, 2020

Use of gingival fibroblasts in the treatment of alopecia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,624,838
App. No.
14/904,151
Granted
Apr 21, 2020
Kind
B2
Abstract

The present invention relates to the use of gingival fibroblast-derived products to reduce hair loss and promote hair growth. Specifically, the invention relates to a product derived from gingival fibroblasts to be used in the treatment or prevention of alopecia, as well as in the promotion of natural hair growth and/or in the control of natural hair loss.

Claims (6)

1. A method for limiting hair/body hair loss and/or promoting the growth of hair/body hair and/or increasing the density of hair follicles in an individual, comprising administering an effective quantity of a gingival fibroblast-derived product to the individual to limit hair/body hair loss and/or to promote the growth of hair/body hair and/or to increase the density of hair follicles in the individual.

2. The method according to claim 1 , wherein the hair loss and/or hair growth and/or density of hair follicles are natural.

3. The method according to claim 1 , wherein the gingival fibroblast-derived product is selected from the group consisting of gingival fibroblasts, gingival fibroblasts from a culture, a gingival fibroblast extract and a gingival fibroblast conditioned medium.

4. The method according to claim 1 , wherein the gingival fibroblast is heterologous, autologous or allogeneic.

5. The method according to claim 1 , wherein the gingival fibroblast-derived product is administered in association with at least one anti-hair loss agent.

6. The method according to claim 1 , wherein the gingival fibroblast-derived product is administered in association with at least one anti-hair loss agent selected from the group consisting of finasteride and minoxidil.

Assignments (3)
CHANGE OF NAME Recorded Mar 25, 2022
From: UNIVERSITÉ DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059504/0225 →
MERGER Recorded Jul 22, 2021
From: UNIVERSITE DE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 056958/0603 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2016
From: LAFONT, ANTOINE; LINARD, CHRISTINE; COULOMB, BERNARD; LATAILLADE, JEAN-JACQUES
To: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE; ETAT FRANCAIS - MINISTERE DE LA DEFENSE - DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES; UNIVERSITE PARIS DESCARTES
Reel/Frame 038352/0970 →